CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
接受抗 CD20 单克隆抗体治疗的患者中 SARS-CoV-2 感染迁延不愈：鼻咽 RT-PCR 阴性带来的诊断挑战及 COVID-19 高滴度恢复期血浆的成功治疗
英文原题：Prolonged SARS-CoV-2 Infection in Patients Receiving Anti-CD20 Monoclonal Antibodies: A Diagnostic Challenged by Negative Nasopharyngeal RT-PCR and Successful Treatment with COVID-19 High-Titer Convalescent Plasma.
查看英文原题
Prolonged SARS-CoV-2 Infection in Patients Receiving Anti-CD20 Monoclonal Antibodies: A Diagnostic Challenged by Negative Nasopharyngeal RT-PCR and Successful Treatment with COVID-19 High-Titer Convalescent Plasma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
我们在本文中重点介绍了4例目前正在接受抗CD20单克隆抗体（mAbs）如ocrelizumab和rituximab治疗多发性硬化或类风湿性多关节炎的重度免疫功能低下患者中类似的COVID-19肺炎迁延性呼吸道表现。所有患者鼻咽拭子标本的实时逆转录聚合酶链反应均为阴性。SARS-CoV-2感染经支气管肺泡灌洗液确诊。所有患者均接受了高效价疫苗接种后COVID-19恢复期血浆治疗并完全康复。
展开英文摘要原文
We highlighted in this current paper similar prolonged respiratory presentation with COVID-19 pneumonia in four severely immunocompromised patients currently being treated with anti-CD20 monoclonal antibodies (mAbs), such as ocrelizumab and rituximab, for multiple sclerosis or rheumatoid polyarthritis.
Real-time reverse transcription-polymerase chain reaction on a nasopharyngeal swab specimen was negative in all patients. SARS-CoV-2 infection was confirmed from bronchoalveolar lavage fluid. A high titer of post-vaccine COVID-19 convalescent plasma was administered with complete recovery in all patients.
论文信息
- 作者
- Da Silva L、Klopfenstein T、Gendrin V、Clouet J、Toko L、Richier Q、Leriche T、Nicolas R
- 单位
- Infectious Diseases Department, Nord Franche-Comté Hospital, 90400 Trevenans, France.France
- 文献类型
- 病例报告
- 期刊
- Viruses2023 Nov 7
- 原文标识
- PubMed 38005897 · DOI 10.3390/v15112220
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →